Ieq Capital LLC Takes Position in Enanta Pharmaceuticals, Inc. $ENTA

Ieq Capital LLC purchased a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 38,508 shares of the biotechnology company’s stock, valued at approximately $561,000.

A number of other institutional investors have also made changes to their positions in the stock. Meeder Asset Management Inc. acquired a new position in Enanta Pharmaceuticals in the fourth quarter valued at about $32,000. Seven Fleet Capital Management LP acquired a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth about $36,000. Strs Ohio acquired a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth about $50,000. Clearstead Trust LLC bought a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter valued at about $74,000. Finally, Quarry LP bought a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at about $81,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, June 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Finally, Wall Street Zen lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 22nd. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $19.50.

Enanta Pharmaceuticals Trading Down 1.4%

NASDAQ:ENTA opened at $13.60 on Friday. Enanta Pharmaceuticals, Inc. has a 1 year low of $7.05 and a 1 year high of $17.15. The stock has a 50-day moving average price of $13.59 and a two-hundred day moving average price of $13.48. The stock has a market cap of $396.10 million, a price-to-earnings ratio of -5.64 and a beta of 0.98.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%.The business had revenue of $14.36 million for the quarter, compared to analyst estimates of $16.76 million. Sell-side analysts forecast that Enanta Pharmaceuticals, Inc. will post -2.36 earnings per share for the current year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.